BioToxTech Co Rule of 40
The Rule of 40 of BioToxTech Co (086040.KQ) as of Oct 16, 2026 is 3.50 %. In the previous year, Rule of 40 was 13.48 % — a change of -74.05% (lower).
Get this data via API
Financial Data API
Rule of 40
3.50 %
YoY
-74.05%
Last updated:
Rule of 40 of BioToxTech Co is 2025 3.50 % . Rule of 40 of BioToxTech Co was 2024 13.48 % . It decreases by -74.05% lower compared to the previous year.
The BioToxTech Co Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
6.83 KRW
Jan 1, 2019
-10.18 KRW
Jan 1, 2020
4.26 KRW
Jan 1, 2021
36.50 KRW
Jan 1, 2022
16.61 KRW
Jan 1, 2023
-37.70 KRW
Jan 1, 2024
13.48 KRW
Jan 1, 2025
3.50 KRW
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 3.50 % | -74.05% | |
| 13.48 % | -135.75% | |
| -37.70 % | -327.02% | |
| 16.61 % | -54.50% | |
| 36.50 % | +757.48% | |
| 4.26 % | -141.83% | |
| -10.18 % | -248.91% | |
| 6.83 % | -70.81% | |
| 23.41 % | -45.00% | |
| 42.57 % | -379.58% | |
| -15.23 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
BioToxTech Co Stock analysis
What does BioToxTech Co do? BioToxTech Co Ltd, listed on the Korea Exchange under ticker 086040.KQ, is a South Korean company operating in the Health Care sector, specifically within Life Sciences Tools & Services. Headquartered in Cheongju, Chungcheongbuk-do, the company provides non-clinical drug trial services. It conducts safety evaluation research, including general and local toxicity tests, reproductive and developmental tests, genotoxicity assessments, immunotoxicity evaluations, carcinogenicity studies, safety pharmacology tests, ecotoxicology examinations, histopathology analyses, and hematology tests. The firm also offers efficacy evaluation research for medical supplies, health supplements, and cosmetics. Additionally, BioToxTech provides analysis research services such as pharmacokinetics (PK) and toxicokinetics (TK) testing, along with validation and bioanalysis services. The company went public on September 21, 2007, and acquired a 60% stake in a newly established subsidiary on March 13, 2013. Its website is https://www.biotoxtech.com/. BioToxTech focuses on supporting pharmaceutical and biotechnology industries through comprehensive preclinical research services, ensuring product safety and efficacy before clinical trials. BioToxTech Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about BioToxTech Co stock
Rule of 40 of BioToxTech Co is 3.50 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — BioToxTech Co
All Key Metrics — BioToxTech Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth